PACS Group, Inc. (NYSE:
PACS) stock saw a noteworthy uptick of 45% in yesterdays extended market trading. With the asset set to break the $16 resistance, should it achieve that fit, the $25 resistant isn’t far fetched .
With the RSI at 71, this connotes
PACS is sparsely overbought however, with increased buying momentum,
PACS will nullify that thesis.
In the same vein, failure to bridge the $16 resistant might resort to a consolidated move to the $10 support.
In another news, PACS Group Intends to Release Third Quarter 2025 Earnings and Submit SEC Filings on November 19, 2025.
About PACS™
PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate 320 post-acute care facilities across seventeen states serving over 30,000 patients daily.
With the RSI at 71, this connotes
In the same vein, failure to bridge the $16 resistant might resort to a consolidated move to the $10 support.
In another news, PACS Group Intends to Release Third Quarter 2025 Earnings and Submit SEC Filings on November 19, 2025.
About PACS™
PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate 320 post-acute care facilities across seventeen states serving over 30,000 patients daily.
免責事項
これらの情報および投稿は、TradingViewが提供または承認する金融、投資、取引、またはその他の種類の助言もしくは推奨であることを意図したものではなく、またこれらに該当するものでもありません。詳細は利用規約をご覧ください。
免責事項
これらの情報および投稿は、TradingViewが提供または承認する金融、投資、取引、またはその他の種類の助言もしくは推奨であることを意図したものではなく、またこれらに該当するものでもありません。詳細は利用規約をご覧ください。
